News

01 Dec 2017

Incentives for Innovation: the story of Gilenya by Novartis

With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcar...

Read more
30 Nov 2017

EBE Concept Paper: Management and Control of Raw Materials Used in the Manufacture of Biological Medicinal Products

Effective management and control of raw materials (RM) used in the manufacture of biological medicinal products requires an appropriate framework to identify and focus on critical aspects that must be...

Read more
24 Nov 2017

Incentives, IP and smaller companies – the story of Transgene

How Transgene wants to change patients’ lives by improving health outcomes Transgene S.A., founded in December 1979, and part of the French Institut Mérieux since 1994, focuses on designing...

Read more
17 Nov 2017

Incentives, IP and smaller companies – the story of Vaxeal

Vaxeal Holding SA is headquartered in Vevey, Switzerland, with operations in Evry and Paris, France. The company was created in 2009. It develops therapeutic vaccines in combination with immune ch...

Read more
10 Nov 2017

Incentives, IP and smaller companies – the story of Chiesi and Holostem

Chiesi and Holostem Terapie Avanzate have jointly developed Holoclar, the first stem-cell-based product to be approved in Europe. Chiesi licenses the international marketing authorization for Holo...

Read more
02 Nov 2017

Incentives, IP and smaller companies – the story of TiGenix

How TiGenix wants to change patients’ lives by improving health outcomes TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced Belgian biopharmaceutical SME with operations in Madrid, S...

Read more
24 Oct 2017

Incentives, IP and smaller companies – the story of ProAxsis

How ProAxsis helps to change patients’ lives by improving diagnostics ProAxsis Limited is a spin out from Queen’s University of Belfast, and based in Belfast, Ireland. Since its foundation...

Read more
18 Oct 2017

Incentives, IP and smaller companies – the story of CureVac

Infographic - Case Story Curevac How CureVac helps to change patients’ lives CureVac, a biopharmaceutical company headquartered in Tübingen, Germany, has grown from three original founde...

Read more
13 Oct 2017

6th EBE Annual Regulatory Conference “Realising the potential of advanced therapies for patients”

5 December 2017,  CCT South Quay Venue – Thames Quay, 193 Marsh Wall, London, E14 9SG, United Kingdom  Draft Agenda Register  Ten years after adoption of the EU regulation on advanc...

Read more
10 Oct 2017

EBE and EFPIA call on the EU Commission and Member States to improve transparency on Hospital Exemptions for Advanced Therapies

“Therapies for the future - Exploring solutions for innovative treatments in Europe” will take place at the European Parliament  on 11 October 2017. In advance of this significant discussion...

Read more
1 2 3 4 7